Jump to ContentJump to Main Navigation
Show Summary Details

LaboratoriumsMedizin - Journal of Laboratory Medicine

Offizielles Organ der Deutschen Vereinten Gesellschaft für Klinische Chemie und Laboratoriumsmedizin e.V. (DGKL) und affiliiert mit der Österreichischen Gesellschaft für Laboratoriumsmedizin und Klinische Chemie (ÖGLMKC)

Editor-in-Chief: Schuff-Werner, Peter

Editorial Board Member: Ahmad-Nejad, Parviz / Bidlingmaier, Martin / Borucki, Katrin / Karsten, Conrad / Fraunberger, Peter / Ghebremedhin, Beniam / Holdenrieder, Stefan / Kiehntopf, Michael / Klein, Hanns-Georg / Klouche, Mariam / Kohse, Klaus P. / Kratzsch, Jürgen / Luppa, Peter B. / März, Winfried / Nebe, Carl Thomas / Orth, Matthias / Ruf, Andreas / Sack, Ulrich / Steimer, Werner / Weber, Bernard / Wieland, Eberhard / Tumani, Hayrettin / Zettl, Uwe K.

6 Issues per year

IMPACT FACTOR 2015: 0.104
5-year IMPACT FACTOR: 0.180

SCImago Journal Rank (SJR) 2014: 0.151
Source Normalized Impact per Paper (SNIP) 2014: 0.172
Impact per Publication (IPP) 2014: 0.313

See all formats and pricing
Volume 34, Issue 5 (Jan 2010)


Antiplatelet drugs in cardiology: current trends in therapy and monitoring1

Matthias Orth
  • Vinzenz von Paul Kliniken gGmbH, Institute of Laboratory Medicine, Stuttgart, Germany
/ Alexander Eduard Rosler
  • Vinzenz von Paul Kliniken gGmbH, Institute of Laboratory Medicine, Stuttgart, Germany
Published Online: 2010-11-11 | DOI: https://doi.org/10.1515/JLM.2010.051et


Dual platelet inhibition therapy with a P2Y12-inhibitor and with acetylsalicylic acid is the standard of care in patients with acute coronary syndrome or after implantation of coronary stents. Clopidogrel is the most often used P2Y12-inhibitor and Prasugrel has recently been approved. Clopidogrel dosing is very complex because of highly heterogeneous inter-individual pharmacokinetics due to genetic polymorphisms and interactions with concomitant medication. Optimization of platelet inhibition therapy is pivotal because platelet inhibitors are one of the most frequently used drugs and overdosing as well as underdosing has enormous consequences. For optimization, pharmacogenetic tests as well as platelet function tests have been developed. Wide arrays of platelet function tests are available with very different complexity and different results. With appropriate point-of-care-tests, dosing can be adjusted immediately. However, pharmacogenetic tests as well as platelet function tests have not yet demonstrated their benefit in prospective studies.

Keywords: acute coronary syndrome; clopidogrel; point-of-care-testing; Prasugrel; P2Y12 receptor

About the article

Correspondence: Priv.-Doz. Dr. med. Matthias Orth, Institute of Laboratory Medicine, Vinzenz von Paul Kliniken gGmbH, Adlerstrasse 7, 70199 Stuttgart, Germany Tel.: +49 711/6489-2760 Fax: +49 711/6489-2688

Published Online: 2010-11-11

Published in Print:

Citation Information: LaboratoriumsMedizin, ISSN (Online) 1439-0477, ISSN (Print) 0342-3026, DOI: https://doi.org/10.1515/JLM.2010.051et. Export Citation

Comments (0)

Please log in or register to comment.
Log in